Skip to main content

New Steps Towards a Male Birth Control Pill

Medically reviewed by Carmen Pope, BPharm. Last updated on May 24, 2024.

By Dennis Thompson HealthDay Reporter

FRIDAY, May 24, 2024 -- For decades, the responsibility for birth control has fallen largely on women, but new research suggests a birth control pill for men might one day become a reality.

How does it work? It targets a protein required for fertility, scientists report.

The protein, called serine/threonine kinase 33 (STK33), is enriched in the testicles and is specifically required to create functional sperm, they explained.

A drug that inhibits STK33, called compound CDD-2807, blocked the ability of male lab mice to fertilize female mice, researchers reported May 23 in the journal Science.

“We were pleased to see that the mice did not show signs of toxicity from CDD-2807 treatment, that the compound did not accumulate in the brain and that the treatment did not alter testis size,” said researcher Courtney Sutton, a postdoctoral fellow in pathology at Baylor College of Medicine in Houston.

“Importantly, the contraceptive effect was reversible,” Sutton added in a Baylor news release. “After a period without compound CDD-2807, the mice recovered sperm motility and numbers and were fertile again.”

Previous research had shown that naturally occurring mutations in STK33 leads to infertility in both mice and men by causing abnormal sperm with poor movement. These mutations cause no other health problems.

“STK33 is therefore considered a viable target with minimal safety concerns for contraception in men,” said researcher Dr. Martin Matzuk, director of the Center for Drug Discovery at Baylor.

The research team screened billions of different compounds to discover ones that would effectively inhibit STK33, researchers said. They then generated modified versions of the most effective compounds to make them more stable and potent.

“Among these modified versions, compound CDD-2807 turned out to be the most effective,” said lead researcher Angela Ku, a staff scientist with Baylor.

The researchers then tested different doses and treatment regimens of CDD-2807 in lab mice, to see how well it worked.

“In the next few years, our goal is to further evaluate this STK33 inhibitor and compounds similar to CDD-2807 in primates, to determine their effectiveness as reversible male contraceptives,” Matzuk said.

Sources

  • Baylor College of Medicine, news release, May 23, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

FDA Tells Vaccine Makers to Target New COVID Variant for Fall

FRIDAY, June 14, 2024 -- COVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot of the JN.1 variant that spread widely last winter, the...

Just 1 in 20 Animal Studies Yield Treatments That Make it to Humans

FRIDAY, June 14, 2024 -- Animal studies are often considered a first step in finding new drugs and treatments for human diseases, but a new review has discovered that precious few...

Swimming 'Microbots' Could Speed Meds to Lung Tumors, Early Study Suggests

FRIDAY, June 14, 2024 -- Scientists have developed microscopic robots capable of swimming through the lungs to deliver chemotherapy directly to lung cancer cells. In early...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.